P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

Detalles Bibliográficos
Autores principales: Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009801/
http://dx.doi.org/10.1097/01.HS9.0000829624.40467.0d
_version_ 1784687342733230080
author Popat, R
Badros, A
Kumar, S
Rodriguez-Otero, P
Cohen, A
Manier, S
Voorhees, P
Gay, F
Rifkin, R
Martin, T
Chari, A
Weisel, K
Farooq, A
Jeng, B
Chng, W
Lee, H
Berdeja, J
Jadhav, V
Tosolini, A
Eliason, L
Palumbo, A
Dimopoulos, M
Lonial, S
Trudel, S
Richardson, P
Terpos, E
author_facet Popat, R
Badros, A
Kumar, S
Rodriguez-Otero, P
Cohen, A
Manier, S
Voorhees, P
Gay, F
Rifkin, R
Martin, T
Chari, A
Weisel, K
Farooq, A
Jeng, B
Chng, W
Lee, H
Berdeja, J
Jadhav, V
Tosolini, A
Eliason, L
Palumbo, A
Dimopoulos, M
Lonial, S
Trudel, S
Richardson, P
Terpos, E
author_sort Popat, R
collection PubMed
description
format Online
Article
Text
id pubmed-9009801
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90098012022-04-18 P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? Popat, R Badros, A Kumar, S Rodriguez-Otero, P Cohen, A Manier, S Voorhees, P Gay, F Rifkin, R Martin, T Chari, A Weisel, K Farooq, A Jeng, B Chng, W Lee, H Berdeja, J Jadhav, V Tosolini, A Eliason, L Palumbo, A Dimopoulos, M Lonial, S Trudel, S Richardson, P Terpos, E Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9009801/ http://dx.doi.org/10.1097/01.HS9.0000829624.40467.0d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Poster
Popat, R
Badros, A
Kumar, S
Rodriguez-Otero, P
Cohen, A
Manier, S
Voorhees, P
Gay, F
Rifkin, R
Martin, T
Chari, A
Weisel, K
Farooq, A
Jeng, B
Chng, W
Lee, H
Berdeja, J
Jadhav, V
Tosolini, A
Eliason, L
Palumbo, A
Dimopoulos, M
Lonial, S
Trudel, S
Richardson, P
Terpos, E
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title_full P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title_fullStr P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title_full_unstemmed P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title_short P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
title_sort p13: can patient-reported ocular symptoms guide dose modifications in patients with relapsed/refractory multiple myeloma receiving belantamab mafodotin?
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009801/
http://dx.doi.org/10.1097/01.HS9.0000829624.40467.0d
work_keys_str_mv AT popatr p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT badrosa p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT kumars p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT rodriguezoterop p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT cohena p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT maniers p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT voorheesp p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT gayf p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT rifkinr p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT martint p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT charia p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT weiselk p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT farooqa p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT jengb p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT chngw p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT leeh p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT berdejaj p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT jadhavv p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT tosolinia p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT eliasonl p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT palumboa p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT dimopoulosm p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT lonials p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT trudels p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT richardsonp p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin
AT terpose p13canpatientreportedocularsymptomsguidedosemodificationsinpatientswithrelapsedrefractorymultiplemyelomareceivingbelantamabmafodotin

Ejemplares similares